Advances in the diagnosis and treatment of progressive supranuclear palsy
Progressive supranuclear palsy(PSP)is considered an atypical form of Parkinsonism,with a prevalence estimated at around 5-7 per 100 000 individuals.The condition is defined by four primary clinical features:ocular motor dysfunction(O),postural instability(P),akinesia(A),and cognitive dysfunction(C).Different combinations of these core features give rise to at least seven distinct clinical phenotypes classified as'probable'or'possible'.While the exact pathophysiology of PSP remains somewhat uncertain,research suggests that Tau dysfunction plays a significant role.Challenges such as the absence of reliable biomarkers,difficulties in early clinical detection,and limited understanding of the precise pathological mechanisms hinder the development of effective treatments capable of altering the disease's progression.This article provides an overview of recent progress in clinical diagnostic criteria,biomarkers,and treatment strategies for PSP.
NETL
NSTL
万方数据
